REGN vs TT · P/E 14, rev $14.34B vs P/E 36, rev $21.32B
Regeneron Pharmaceuticals Inc (REGN) versus Trane Technologies plc (TT) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Trane Technologies plc (TT) is a building products & equipment company listed on NYSE.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported TT revenue for 2025-12-31 was $21.32B. Net income was $2.92B. Revenue was up 7.5% from 2024-12-31 to 2025-12-31. TT currently screens at market cap $104.45B and trailing P/E 36.2.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. TT currently screens at market cap $104.45B and trailing P/E 36.2.
Not investment advice. Open the REGN and TT stock pages for the full models.
Not investment advice.